Enliven Therapeutics (ELVN) Liabilities and Shareholders Equity (2019 - 2026)
Enliven Therapeutics' Liabilities and Shareholders Equity was $910.22 million in Q2 2026, up 80.6% from $503.89 million a year earlier and up 95.8% from the prior quarter.
Powered by 
Analysis
Enliven Therapeutics (ELVN) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
At the end of FY2025, Liabilities and Shareholders Equity at Enliven Therapeutics came in at $476.17 million, up 46.2% from FY2024.
- Liabilities and Shareholders Equity has now increased for three consecutive years, with a five-year compound annual growth rate of 39.3% (FY2020 to FY2025).
- In earlier years, Liabilities and Shareholders Equity was $325.76 million in FY2024 (+19.8%), $271.87 million in FY2023 (+226.4%), $83.3 million in FY2022 (-11.1%) and $93.65 million in FY2021 (+3.1%).
- The Q2 2026 figure marks the highest quarterly Liabilities and Shareholders Equity in data going back to Q4 2019.
- Compared with a year earlier, Liabilities and Shareholders Equity has increased for five straight quarters, with growth averaging 39.3% over the last eight quarters.
- The best year-over-year quarter for Liabilities and Shareholders Equity over five years was Q3 2023 (growth of 363.7%); the worst was Q3 2022 (a decline of 44.8%).
- Per Business Quant data, ELVN's Liabilities and Shareholders Equity in the three quarters before Q2 2026 was $464.85 million (Q1 2026), $476.17 million (Q4 2025) and $490.88 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Enliven Therapeutics | 3.36 Bn | 3.36 Bn | - | 910.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 910.22 Mn |
| Mar 31, 2026 | 464.85 Mn |
| Dec 31, 2025 | 476.17 Mn |
| Sep 30, 2025 | 490.88 Mn |
| Jun 30, 2025 | 503.89 Mn |
| Mar 31, 2025 | 302.57 Mn |
| Dec 31, 2024 | 325.76 Mn |
| Sep 30, 2024 | 305.43 Mn |
| Jun 30, 2024 | 327.04 Mn |
| Mar 31, 2024 | 342.78 Mn |
| Dec 31, 2023 | 271.87 Mn |
| Sep 30, 2023 | 274.04 Mn |
| Jun 30, 2023 | 288.50 Mn |
| Mar 31, 2023 | 302.87 Mn |
| Dec 31, 2022 | 83.30 Mn |
| Sep 30, 2022 | 59.10 Mn |
| Jun 30, 2022 | 64.67 Mn |
| Mar 31, 2022 | 81.60 Mn |
| Dec 31, 2021 | 93.65 Mn |
| Sep 30, 2021 | 107.03 Mn |
API Access
Enliven Therapeutics Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ELVN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "ELVN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ELVN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();